¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"modification and restriction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • arch and band appliance
    Ȱ¶ìÀåÄ¡
  • bilateral cleft lip and palate
    ¾çÂÊÀÔ¼úÀÔõÀå°¥¸²Áõ, ¾çÃø±¸¼ø±¸°³¿­
  • bread-and-butter pericarditis
    »§¹öÅ͸ð¾ç½ÉÀ帷¿°
  • complementary and alternative medicine
    º¸Ãæ´ë¾ÈÀÇÇÐ, º¸¿Ï´ëüÀÇÇÐ
  • Center for Disease Control and Prevention
    Áúº´°ü¸®¿¹¹æ¼¾ÅÍ
  • dilatation and curettage
    Àڱñܾ(¼ú), ÀÚ±Ã¼ÒÆÄ(¼ú)
  • foot-and-mouth disease
    ÀԹߺ´, ±¸Á¦¿ª
  • half and half nail
    ¹Ý°ú¹Ý¼Õ¹ßÅé
  • incision and drainage
    1. Àý°³¹è³ó(¼ú) 2. Àý°³¹è¾×(¼ú)
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • kidney ureter and bladder
    ÄáÆÏ¿ä°ü¹æ±¤´Ü¼øÃÔ¿µ
  • law of weights and measures
    °è·®¹ý
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anxious and fearful personality
    ºÒ¾È°øÆ÷ÀΰÝ
  • arch and band appliance
    Ȱ¶ìÀåÄ¡
  • split pin and tube attachment
    À¯ÃʺÐÇÒÇÕÁ¤
  • babbling and lalling stage
    ¿Ë¾ËÀ̽ñâ
  • bilateral cleft lip and palate
    ¾çÂÊÀÔ¼úÀÔõÀå°¥¸²Áõ
  • bread and butter pericarditis
    »§¹öÅ͸ð¾ç½ÉÀ帷¿°
  • dilatation and curettage
    ÀڱøñÈ®Àå±Ü¾î³¿¼ú, °æ°üÈ®ÀåÀÚ±Ã¼ÒÆÄ¼ú
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⸸¼º¿ø¹Ýż±ÇǺο°
  • foot-and-mouth disease
    ÀԹ߱Áº´, ±¸Á¦¿ª
  • incision and drainage
    Àý°³¹è³ó
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • embryonal and botryoid rhabdomyosarcoma
    ¹è¾ÆÆ÷µµÈ¾¹®±ÙÀ°Á¾
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • PANSS=Positive and Negative Syndrome Scale
    ¾ç¼º À½¼º ÁõÈıº ôµµ
  • SADS, Schedule for Affective Disorders and Schizophrenia
    Á¤µ¿Àå¾Ö¿Í Á¤½ÅºÐ¿­º´ÀÇ Áø´ÜÀ» À§ÇÑ ¸ñ·Ï
  • SOFAS, Social and Occupational Functioning Assessment Scale
    »çȸ-Á÷¾÷±â´ÉÆò°¡Ã´µµ
  • SONAR(Sound Navigation and Ranging)
    ¼Ò³ª
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • alternate hot and cold caloric examination
    ³Ã¿Â±³´ë(¿Âµµ)Àڱذ˻ç(ÕÒè®Îßû»è®öôô§Ð½ËþÞÛ).
  • ambient temperature and pressure saturated with water vapor =ATP
    ½Ç¿Â´ë±â¾Ð ¼öÁõ±â Æ÷È­»óÅÂ
  • american society of therapeutic radiology and onco
    logy (ASTRO) ¹Ì±¹¹æ»ç¼±Á¾¾çÇÐȸ
  • aphthous fever =foot and mouth disease
    ¾ÆÇÁŸ¼º¿­(¡­æð).
  • glioma of optic nerve and chiasm
    ½Ã½Å°æ±³Â÷ ±³¼¼Æ÷Á¾.
  • glycerin and potash solution
    ±Û¸®¼¼¸° Ä®·ý¾×.
  • gray matter (nuclei and columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
  • half and half nail
    ¹Ý¹Ý Á¶°©
  • hand and foot disease
    ¼ö Á· Áúȯ£¨â¢ðëòðü´£©£¬¼Õ ¹ß º´, ¼ö Á· º´ (â¢ðëÜ»).
  • hand foot and mouth disease
    ¼Õ¹ßÀÔº´ (¡­Ü»), ¼öÁ·±¸º´(â¢ðëϢܻ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • legal restriction
    ¹ýÀûÇѰè(ÊṴ̀˭).
  • mst ii restriction enzyme
    Mst II Á¦ÇÑÈ¿¼Ò(¡­ ð¤ùÚý£áÈ)
  • restriction analysis
  • restriction endonuclease
    Á¦ÇÑ¿£µµ´ºÅ¬¸®¿¡ÀÌÁî
  • restriction endonuclease
    Á¦ÇÑÈ¿¼Ò
  • restriction endonucleases
    Á¦ÇÑÇÙ»ê ³»ºÎ°¡¼öºÐÇØÈ¿¼Ò
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò(ð¤ùÚý£áÈ).
  • restriction enzymes
    Á¦ÇÑÈ¿¼Ò(ð¤ùÚý£áÈ)
  • restriction fragment length polymorphism
    Á¦ÇѼ¼Æí±æÀÌ´ÙÇü¼º(ð¤ùÚ¼¼Æí¡­Òýû¡à÷)
  • restriction fragment length polymorphism,in cystic fibrosis
    ³¶¼º¼¶À¯Áõ(ÀÇ)¡­(Ò¥àõàéë«ñø¡­)
  • restriction fragment length polymorphism analysis
    Á¦ÇÑÀý´Ü±æÀÌ´ÙÇüÁõºÐ¼®
  • restriction fragment length polymorphism=RFLP
    Á¦ÇÑÀýÆí±æÀ̴پ缺
  • restriction map
    Á¦ÇÑÈ¿¼ÒÁöµµ
  • restriction, H-2
    H-2 Â÷À̼ö¹Ý ¸é¿ª»óÈ£ÀÛ¿ëÁ¦ÇÑ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Mesenteries and peritoneal folds
    âÀÚ°£¸· ¹× º¹¸·ÁÖ¸§
    [¿¾ ¿ë¾î] Àå°£¸·
  • Coeloms and septa
    ü°­°ú Áß°Ý
    [¿¾ ¿ë¾î] ü°­°ú Áß°Ý
  • Gray matter (Nuclei and Columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
    [¿¾ ¿ë¾î] ȸ¹éÁú
  • Cartilages and Articulations of Larynx
    Èĵο¬°ñ ¹× ÈĵΰüÀý
    [¿¾ ¿ë¾î] Èĵο¬°ñ ¹× ÈĵΰüÀý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • DNA modification
    "DNA ¼ö½Ä(áóãÞ), (ÔÒ) postreplicative modification"
  • DNA restriction enzyme
    DNA Á¦ÇÑ È¿¼Ò(ð¤ùÚý£áÈ) (ÔÒ) restriction enzyme
  • host-controlled modification
    ¼÷ÁÖÁ¦¾î ¼ö½Ä(âÖñ«ð¤åÙáóãÞ)
  • host-controlled restriction
    ¼÷ÁÖÁ¦¾î Á¦ÇÑ(âÖñ«ð¤åÙð¤ùÚ)
  • host-induced modification
    ¼÷ÁÖÀ¯µµ ¼ö½Ä(âÖñ«ë¯ÓôáóãÞ)
  • modification
    ¼ö½Ä(áóãÞ)
  • modification allele
    ¼ö½Ä´ë¸³À¯ÀüÀÚ(áóãÞÓߨ¡ë¶îîí­)
  • modification enzyme
    ¼ö½ÄÈ¿¼Ò(áóãÞý£áÈ)
  • modification gene
    ¼ö½ÄÈ¿¼Ò À¯ÀüÀÚ(áóãÞý£áÈë¶îîí­)
  • modification methylase
    ¼ö½Ä(áóãÞ)¸ÞÆ¿·¹À̽º
  • postreplicative modification
    º¹Á¦ÈÄ ¼ö½Ä(áóãÞ)
  • post-trancriptional modification
    Àü»çÈÄ ¼ö½Ä(ï®ÞÐý­áóãÞ)
  • post-translational modification
    ¹ø¿ªÈÄ ¼ö½Ä(Ûèæ»ý­áóãÞ)
  • protein modification
    ´Ü¹éÁú ¼ö½Ä(Ó±ÛÜòõáóãÞ)
  • restriction
    Á¦ÇÑ(ð¤ùÚ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RFLP restriction fragment length polymorphism
Bmod behavior modification
CM California mastitis [test]; calmodulin; capreomycin; carboxymethyl; cardiac murmur; cardiac muscle; ...
CMS children's medical services; Christian Medical Society; chronic myelodysplastic syndrome; chromosome...
EBM electrophysiologic behavior modification; epidermal basement membrane; evidence-based medicine; expr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MDRD Modification of Diet in Renal Disease
ARDRA Amplified ribosomal DNA restriction analysis
CR Caloric restriction
DR Diet restriction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cheek and tongue retractor
    Çù¼³ °ßÀαâ
  • child abuse and neglect
    ¾Æµ¿ Çдë¿Í ¹æÄ¡
  • communication codes and characteristics
    È­ÀÇ ºÎÈ£¿Í ¼ºÁú
  • congenital and developmental bone disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º °ñ Àå¾Ö
  • congenital and developmental muscle disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º ±ÙÀå¾Ö
    Ãâ»ý ½ÃºÎÅÍ ±ÙÀúÇϸ¦ ³ªÅ¸³»°í Èå´ÃÈå´ÃÇÑ ¾ÆÀÌ. flo
  • connective tissue sheath of Key and Retzius
    Ű-·¹Ä¡¿ì½ºÀÇ °áÇÕ Á¶Á÷ ÃÊ
    ½Å°æ³»¸·, ƯÈ÷ ½Å°æ¼¶À¯ Á¾¸»Áö ÁÖÀ§ÀÇ ¾ãÀº ¿¬Àå.
  • crown and loop space maintainer
    Å©¶ó¿î¿£µå ·çÇÁÇü °£°Ý À¯Áö ÀåÄ¡
  • cultural and ethnic factor
    ¹®È­ ¹ÎÁ·Àû ¿äÀÎ
  • D and C ÀÚ±ÃÀÇ °æºÎ È®Àå°ú ³»¸· ¼ÒÆÄ.

    D factor

    D-ÀÎÀÚ
  • development of speech and language
    ÀÇ»ç ¼ÒÅëÀÇ ¹ß´Þ
  • ear nose and throat
    À̺ñÀÎÈİú
    ÈĵÎ, ºñ°­, ÀεΠµîÀ» Àü¹®À¸·Î ÇÏ´Â ÀÇÇÐÀÇ ÇÑ ºÐ°ú.
  • exostosis and osteoma
    ¿Ü°ñÁõ ¹× °ñÁ¾
    »À Á¶Á÷ÀÇ °ú¹ßÀ°Àº Åë»ó ¿ì¿¬È÷ ¹ß°ßµÇ´Â °ÍÀÌ ´ëºÎºÐÀÌ°í °¡²û ÀÓ»óÀûÀ¸·Î Àǹ̰¡ ÀÖ´Â °æ¿ì¸¦ º»´Ù. ÀÓ»óÀûÀ¸·Î ÇǺηΠµ¤Èù µÕ±Ù °ñ Á¶Á÷ÀÌ ¿ÜÀ̵µÀÇ ³»Ãø¿¡¼­ °í¸·À» °¡¸®¸ç °üÂûµÈ´Ù. ÀϺο¡ ±¹ÇÑµÈ ´ÜÀÏÀÇ °ñÁ¾Àº ¿ÜÀ̵µ¸¦ ¿ÏÀüÈ÷ ¸·°Å³ª °¨¿°À» ÀÏÀ¸Å°Áö ¾Ê´Â ÇÑ ¹®Á¦°¡ ¾øÀ¸³ª ¶§·Î Â÷°¡¿î ¹°¿¡ Áö¼ÓÀûÀ¸·Î ³ëÃâµÈ °ÍÀÌ ¿øÀÎÀ¸·Î Áö¸ñµÇ±âµµ ÇÏ´Â ´Ù¹ß¼º °ñÁ¾ÀÇ °æ¿ì´Â Á¡Â÷ ÁøÇàµÇ¾î ¼ö¼úÀÌ ÇÊ¿äÇϱ⵵ ÇÏ´Ù.
  • explosion and fire hazard
    Æø¹ß ÀÎÈ­¼º À§Çè
  • Food and Drug Administration
    ½ÄǰÀǾà±â±¸
  • H and D curve
    Ư¼º °î¼±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
restriction fragment <molecular biology> The fragments of DNA generated by digesting DNA with a specific restriction endonuclease. Each of the fragments ends in a site recognised by that specific enzyme.
(10 Mar 1998)
restriction fragment length polymorphism <molecular biology, technique> A method that allows familial relationships to be established by comparing the characteristic polymorphic patterns that are obtained when certain regions of genomic DNA are amplified (typically by PCR) and cut with certain restriction enzymes.
The variation in the length of DNA fragments produced by a restriction endonuclease that cuts at a polymorphic locus. Such variations are generated by mutations that create or abolish recognition sites for these enzymes.
This is a key tool in DNA fingerprinting, reflecting the existence of different alleles in the individual. Restriction fragment length polymorphism mapping is also used in plant breeding to see if a key trait such as disease resistance is inherited.
In principle, an individual can be identified unambiquously by restriction fragment length polymorphism hence the use of restriction fragment length polymorphism in forensic analysis of blood, hair or semen).
Similarly, if a polymorphism can be identified close to the locus of a genetic defect, it provides a valuable marker for tracing the inheritance of the defect.
Synonym: DNA fingerprinting.
Acronym: RFLP
(12 Jan 1998)
restriction length polymorphism Fragment length polymorphism, the existence of allelic forms recognizable by the length of fragments that result when the nucleotide chain is treated by a specific restriction enzyme that cleaves wherever a particular sequence of nucleotides occurs. A mutation in this sequence changes cleaving and hence the number of fragments.
(05 Mar 2000)
restriction map <molecular biology> Map of DNA showing the position of sites recognised and cut by various restriction endonucleases.
(12 Jan 1998)
restriction mapping Use of restriction endonucleases to analyze and generate a physical map of genomes or genes. The nucleotide sequence determined is often then translated into an amino acid sequence, providing a means for sequencing the protein for which the gene codes, or for which the mRNA is a messenger.
(12 Dec 1998)
restriction methylation The enzymatic addition of methyl groups to selected adenine and cytosine residues to protect from hydrolysis by certain restriction enzymes.
(05 Mar 2000)
restriction nuclease <enzyme, molecular biology> Class of bacterial enzymes that cut DNA at specific sites. In bacteria their function is to destroy foreign DNA, such as that of bacteriophages (host DNA is specifically modified at these sites).
Type I restriction endonucleases occur as a complex with the methylase and a polypeptide that binds to the recognition site on DNA. They are often not very specific and cut at a remote site.
Type II restriction endonucleases are the classic experimental tools. They have very specific recognition and cutting sites. The recognition sites are short, 4-8 nucleotides and are usually palindromic sequences. Because both strands have the same sequence running in opposite directions the enzymes make double stranded breaks, which, if the site of cleavage is off centre, generates fragments with short single stranded tails, these can hybridise to the tails of other fragments and are called sticky ends.
They are generally named according to the bacterium from which they were isolated (first letter of genus name and the first two letters of the specific name). The bacterial strain is identified next and multiple enzymes are given Roman numerals. For example the two enzymes isolated from the R strain of E. Coli are designated Eco RI and Eco RII.
(10 Mar 1998)
restriction site A sequence in DNA that can be recognised and cut by a specific restriction enzyme.
(12 Dec 1998)
restriction-site polymorphism DNA polymorphism in which the sequence of one form of the polymorphism contains a recognition site for a particular endonuclease, but the sequence of the other form lacks such a site.
(05 Mar 2000)
MHC restriction <immunology> Restriction on interaction between cells of the immune system because of the requirement to recognise foreign antigen is association with MHC antigens (major histocompatibility antigens). Thus, cytotoxic T-cells will only kill virally infected cells that have the same Class I antigens as themselves, whereas helper T-cells respond to foreign antigen associated with Class II antigens.
(18 Nov 1997)
DNA restriction enzymes <enzyme> Enzymes that are part of the restriction-modification systems. They catalyze the endonucleolytic cleavage of DNA sequences which lack the species-specific methylation pattern in the host cell's DNA. Cleavage yields random or specific double-stranded fragments with terminal 5'-phosphates. The function of restriction enzymes is to destroy any foreign DNA that invades the host cell. most have been studied in bacterial systems, but a few have been found in eukaryotic organisms. They are also used as tools for the systematic dissection and mapping of chromosomes, in the determination of base sequences of dnas, and have made it possible to splice and recombine genes from one organism into the genome of another.
Registry number: EC 3.1.21
(12 Dec 1998)
ecori restriction enzyme <enzyme, molecular biology> A commonly-used restriction enzyme (enzyme which will cleave the phosphodiester bonds of DNA at specific nucleotide sequences) that came from the bacteria Escherichia coli and recognises the sequence GAATTC.
The enzyme will make a staggered cut of the double-stranded DNA molecule by cutting between the G and A on both strands.
(09 Oct 1997)
lactase restriction An inherited trait in which there is low lactase activity and thus there is defective lactose intestinal metabolism.
Compare: lactase persistence.
(05 Mar 2000)
abstracting and indexing Shortening or summarizing of documents; assigning of descriptors for referencing documents.
(12 Dec 1998)
academies and institutes Organizations representing specialised fields which are accepted as authoritative; may be non-governmental, university or an independent research organization, e.g., national academy of sciences, brookings institution, etc.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • by and by
    ÀÌÀ¹°í
  • by-and-by
    ¹Ì·¡
  • checks and balances
    °ßÁ¦¿Í ±ÕÇü
  • every now and then
    À̵û±Ý
  • here and there
    ¿©±âÀú±â¿¡
  • hide-and-go-seek
    ¼û¹Ù²ÀÁú
  • hide-and-seek
    ¼û¹Ù²ÀÁú
  • hole-and-corner
    ºñ¹ÐÀÇ
  • kith and kin
    ģôÁö±â, Àϰ¡Ä£Ã´
  • now and again
    À̵û±Ý
  • now and then
    ¶§¶§·Î (every ... ... ....)
  • off and on
    ºÒ±ÔÄ¢ÇϰÔ
  • on and on
    °è¼ÓÇÏ¿©
  • once and for all
    ¸¶Áö¸·À¸·Î
  • one and all
    ÇÑ »ç¶÷ ºüÁü¾øÀÌ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á